Add office photos
Employer?
Claim Account for FREE
Novo Nordisk
4.1
based on 957 Reviews
Video summary
Proud winner of ABECA 2024 - AmbitionBox Employee Choice Awards
Company Overview
Company Locations
Working at Novo Nordisk
Company Summary
Novo Nordisk is one of the leading global healthcare company, founded in 1923 and headquartered in Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases.
Overall Rating
4.1/5
based on 957 reviews
5% above
industry average
Highly rated for
Company culture, Job security, Work-life balance
Work Policy
Hybrid
78% employees reported
Monday to Friday
62% employees reported
Flexible timing
75% employees reported
No travel
38% employees reported
View detailed work policy
Top Employees Benefits
Health insurance
94 employees reported
Job/Soft skill training
81 employees reported
Cafeteria
45 employees reported
International/On-site exposure
35 employees reported
View all benefits
Sopra Steria
Success to our employee's well-being? A work-life balance that's simply unbeatable.
Our employees have rated us 4 for Work-Life Balance on AmbitionBox
About Novo Nordisk
Founded in1923 (102 yrs old)
India Employee Count1k-5k
Global Employee Count10k-50k
HeadquartersNew York City,New York, United States
Office Locations
--
Websitenovonordisk.com
Primary Industry
Other Industries
Are you managing Novo Nordisk's employer brand? To edit company information,
claim this page for free
View in video summary
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic diseases.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries.
Managing your company's employer brand?
Claim this Company Page for FREE
AmbitionBox Best Places to Work in India Awards
Best of the best, rated by employees
Novo Nordisk won India’s Largest Employee Choice Awards in Mid-Sized Companies Category.
#3 Top Rated Pharma Company
Share
Novo Nordisk Ratings
based on 957 reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
474
4
242
3
110
2
46
1
85
Category Ratings
4.0
Company culture
4.0
Job security
4.0
Work-life balance
3.9
Skill development
3.8
Work satisfaction
3.7
Salary
3.4
Promotions
Novo Nordisk is rated 4.1 out of 5 stars on AmbitionBox, based on 957 company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Novo Nordisk
based on 910 reviews
4.2
Rated by 275 Women
Rated 4.2 for Company culture and 4.1 for Work-life balance
4.1
Rated by 635 Men
Rated 4.0 for Work-life balance and 4.0 for Company culture
Work Policy at Novo Nordisk
based on 125 reviews in last 6 months
Hybrid
78%
Work from office
21%
Permanent work from home
1%
Novo Nordisk Reviews
Top mentions in Novo Nordisk Reviews
+ 5 more
HCLTech
An opportunity to work for Fortune 500 companies
The biggest brands, the bravest work.
Compare Novo Nordisk with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 957 reviews  | 4.1/5 based on 1.8k reviews | 4.2/5 based on 1.2k reviews | 3.8/5 based on 427 reviews |
Highly Rated for | Work-life balance Job security Company culture | Company culture Skill development Work-life balance | Work-life balance Company culture Skill development | Work-life balance Job security |
Critically Rated for |  No critically rated category | No critically rated category | No critically rated category | Promotions |
Primary Work Policy | Hybrid 78% employees reported | Hybrid 71% employees reported | Hybrid 61% employees reported | Hybrid 92% employees reported |
Rating by Women Employees | 4.2 Good rated by 275 women | 4.1 Good rated by 277 women | 4.2 Good rated by 219 women | 4.0 Good rated by 110 women |
Rating by Men Employees | 4.1 Good rated by 635 men | 4.1 Good rated by 1.5k men | 4.2 Good rated by 903 men | 3.8 Good rated by 286 men |
Job security | 4.0 Good | 3.7 Good | 3.9 Good | 3.9 Good |
View more
Novo Nordisk Salaries
Novo Nordisk salaries have received with an average score of 3.7 out of 5 by 957 employees.
Business Analyst
(335 salaries)
Unlock
₹8 L/yr - ₹22 L/yr
Senior Product Specialist
(208 salaries)
Unlock
₹4.2 L/yr - ₹10.1 L/yr
Product Specialist
(180 salaries)
Unlock
₹3 L/yr - ₹8.5 L/yr
Advanced Business Analyst
(180 salaries)
Unlock
₹10 L/yr - ₹34.3 L/yr
Associate Business Analyst
(154 salaries)
Unlock
₹5.7 L/yr - ₹18 L/yr
Key Account Manager
(119 salaries)
Unlock
₹5.2 L/yr - ₹15.5 L/yr
Senior Associate
(71 salaries)
Unlock
₹5.6 L/yr - ₹12 L/yr
Project Manager
(69 salaries)
Unlock
₹9.2 L/yr - ₹32.5 L/yr
Drug Safety Associate
(58 salaries)
Unlock
₹3 L/yr - ₹7 L/yr
Area Sales Manager
(53 salaries)
Unlock
₹10 L/yr - ₹19.3 L/yr
Novo Nordisk Interview Questions
Interview questions by designation
Top Novo Nordisk interview questions and answers
Get interview-ready with top interview questions
Novo Nordisk Jobs
Popular Designations Novo Nordisk Hires for
Current Openings
Novo Nordisk News
View all
Novo Nordisk, Sanofi face SA insulin antitrust probe
- Novo Nordisk and Sanofi are being investigated in South Africa for potential anti-competitive practices in the human insulin pen market.
- The South African Competition Commission is examining the use of multiple device patents and proprietary designs to exclude competition and hinder other suppliers.
- Novo Nordisk welcomes the investigation and emphasizes their compliance with relevant laws, supporting a competitive market.
- In response to the investigation, Novo Nordisk phased out their easy-to-use insulin pens, instead opting for older vial-based treatments, and ensured adequate access to insulin through other means.
Moneyweb | 5 Mar, 2025
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
- Hims and Hers, a telehealth company, is phasing out its compounded weight loss drugs in response to an FDA update.
- The FDA removed semaglutide injections from its shortage list, leading to a 19% drop in Hims and Hers' stock.
- Hims has been making legal copies of Novo Nordisk's weight loss drugs, Ozempic and Wegovy, at lower prices during a drug shortage.
- Despite this decision, Hims still reported strong revenue growth in the fourth quarter of 2024.
Insider | 25 Feb, 2025
Beware of HIMS, RGTI, and More
- HIMS stock (Him & Hers) lost momentum, closing down by 25.79% on Feb. 21.
- Him & Hers cannot manufacture Novo Nordisk's obesity drugs due to FDA declaring no drug shortage.
- RGTI (Regetti Computing) shares likely to decline after a failed rally on Feb. 21.
- Be cautious of Intel (INTC) stock due to vague rumors of potential buyout by non-American companies.
Baystreet | 24 Feb, 2025
Jobs Reports Due for Next Week
- The report contains jobs numbers from the US and Canada along with their featured earnings for the upcoming week.
- Monday will see the announcement of economic data regarding the S&P's final US manufacturing PMI, Construction spending, ISM manufacturing and Auto Sales for January.
- On Tuesday, reports will be published announcing job openings data and factory orders for December in the US, as well as the Canadian international merchandise trade for December.
- Wednesday will bring information about ADP employment, US trade deficit, the S&P final US services PMI and ISM services.
- Thursday will see the release of the US initial jobless claims, US productivity for Q4 along with featured earnings for companies including Amazon.com Inc., Eli Lilly And Co, and AstraZeneca PLC.
- Friday will announce the US employment report for January, wholesale inventories and Consumer sentiment, along with earnings from Southern Copper Corp, Fortive Corporation and Kimco Realty Corporation.
- This week's earnings reports include Palantir Technologies, NXP Semiconductors NV, IDEXX Laboratories, Char Technologies, LithiumBank Resources Corp, and TMX Group Limited for Monday.
- On Tuesday, earnings for Alphabet Inc, Toyota Motor Corporation, and Merck & Co Inc will be announced.
- Wednesday's earnings reports include those of NovoNordisk, Alibaba Group Holding Ltd and Walt Disney Co.
- Thursday's featured earnings reports include BCE Inc., Bombardier Inc., Canada Goose Holdings Inc, Colliers International Group Inc., Constellation Software Inc and Lightspeed Commerce Inc.
- Friday's earnings reports include ARC Resources, CAE Inc. Unlimited and Canopy Growth Corporation.
Baystreet | 1 Feb, 2025
FDA Approves Ozempic To Treat Kidney Disease
- The FDA has approved Novo Nordisk's Ozempic medication to treat kidney disease in people with Type 2 diabetes, expanding its use within the U.S. market.
- Ozempic can now be used to reduce the impacts of kidney disease, kidney failure, and death from cardiovascular disease in patients with diabetes.
- This decision could transform the treatment of chronic kidney disease, which affects nearly 40 million Americans and is a leading cause of death.
- Ozempic demonstrated health benefits beyond regulating blood sugar and suppressing appetite, contributing to Novo Nordisk's competition with Eli Lilly.
Baystreet | 29 Jan, 2025
S&P Hits New Record
- The S&P 500 reached new records on Friday as optimism around the start of President Donald Trump’s term continued.
- Novo Nordisk rallied more than 7% following positive early-stage results for a weight-loss drug. Texas Instruments slid more than 4% on weak earnings guidance.
- Traders were relieved that there have only been threats on the tariff front from Trump — instead of formal action — during his first few days in the White House.
- All three major averages are on track to post their second positive week, signaling the bull market is back in full force after December’s pullback.
Baystreet | 25 Jan, 2025
S&P Aims for 2nd Weekly Record
- The S&P 500 flirted with new records on Friday as optimism around the start of President Donald Trump’s term continued.
- Novo Nordisk rallied more than 7% following positive early-stage results for a weight-loss drug. Texas Instruments slid more than 4% on weak earnings guidance.
- Excitement toward Trump’s pro-business policies pushed risk assets higher this week with investors focused on his inauguration.
- All three major averages are on track to post their second positive week, signaling the bull market is back in full force after December’s pullback.
Baystreet | 24 Jan, 2025
Stocks on Sale: Novo Nordisk, Viking Therapeutics, Nike, and Bitcoin
- Novo Nordisk (NVO) faced a significant drop in value due to overreaction to Eli Lilly's clinical data
- Novo reported Phase 3 results of its weight loss therapy, but investors are concerned about competition
- Nike (NKE) closed at $77.00 after second-quarter results, focusing on digital channels and reducing excess inventory
- Bitcoin (BTC-USD) dropped to around $97,290 due to the Fed's indication of fewer interest rate cuts in 2025
Baystreet | 23 Dec, 2024
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
- Novo Nordisk's stock tanked after a highly anticipated drug trial disappointed.
- The study showed its new obesity drug helped people lose less weight than expected.
- Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%.
- Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors.
Insider | 20 Dec, 2024
Novo Nordisk Falls on Trial Results
- Shares of Novo Nordisk fell after results of a late-stage trial for its weight loss drug missed expectations.
- The experimental drug, CagriSema, helped patients reduce weight by 22.7%, below the 25% forecasted.
- Novo Nordisk's stock dropped around 18.8% in London trading.
- The trial results are a setback for the potential of CagriSema to become a next-generation obesity drug.
Baystreet | 20 Dec, 2024
Powered by
Novo Nordisk Offices
Compare Novo Nordisk with
Abbott
4.1
Pfizer
4.0
Merck
4.3
Johnson & Johnson
4.0
AstraZeneca
4.1
Bayer
4.1
Roche Holding
5.0
Hetero
3.9
Viatris
4.2
Akums Drugs & Pharmaceuticals Limited
4.4
DIVI'S Laboratories
3.7
Fresenius Kabi
4.2
Piramal Pharma
4.0
Teva Pharmaceuticals
3.9
Sandoz
4.0
Par Pharmaceutical Companies
4.3
Novartis Healthcare
4.1
Apex Laboratories
4.0
Agilent Technologies
4.1
Pfizer Products India
4.1
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Write a review
Share interview
Contribute salary
Add office photos
Companies Similar to Novo Nordisk
Eli Lilly and Company
Pharma
3.8
• 427 reviews
Sanofi
Biotech & Life sciences, Manufacturing, Analytics & KPO, Pharma
4.2
• 1.2k reviews
GlaxoSmithKline Pharmaceuticals
Biotech & Life sciences, Healthcare / Pharma, Manufacturing, Pharma
4.1
• 1.8k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.1k reviews
Johnson & Johnson
Manufacturing, Healthcare
4.0
• 1.4k reviews
AstraZeneca
Biotechnology, Pharma
4.1
• 833 reviews
Bayer
Agriculture, Chemicals / Agri Inputs, Chemicals, Agro Chemicals
4.1
• 738 reviews
5.0
• 1 reviews
Novo Nordisk FAQs
When was Novo Nordisk founded?
Novo Nordisk was founded in 1923. The company has been operating for 102 years primarily in the Pharma sector.
Where is the Novo Nordisk headquarters located?
Novo Nordisk is headquartered in New York City,New York.
How many employees does Novo Nordisk have in India?
Novo Nordisk currently has more than 4,200+ employees in India. Marketing & Communication department appears to have the highest employee count in Novo Nordisk based on the number of reviews submitted on AmbitionBox.
Does Novo Nordisk have good work-life balance?
Novo Nordisk has a work-life balance rating of 4.0 out of 5 based on 900+ employee reviews on AmbitionBox. 75% employees rated Novo Nordisk 4 or above on work-life balance. This rating reflects the company's efforts to help employees maintain a healthy balance between their personal and professional lives. We encourage you to read Novo Nordisk work-life balance reviews for more details
Is Novo Nordisk good for career growth?
Career growth at Novo Nordisk is rated as moderate, with a promotions and appraisal rating of 3.4. 25% employees rated Novo Nordisk 3 or below, while 75% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Novo Nordisk promotions/appraisals reviews for more detailed insights.
What are the pros of working in Novo Nordisk?
Working at Novo Nordisk offers several advantages that make it an appealing place for employees. The company is highly rated for company culture, job security and work life balance, based on 900+ employee reviews on AmbitionBox.
Recently Viewed
REVIEWS
Novo Nordisk
No Reviews
SALARIES
Novo Nordisk
SALARIES
Novo Nordisk
REVIEWS
LTIMindtree
No Reviews
SALARIES
CGI Group
COMPANY BENEFITS
Accenture
No Benefits
REVIEWS
BT Business
No Reviews
JOBS
Coforge
No Jobs
SALARIES
Novo Nordisk
SALARIES
Coforge
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
